item management s discussion and analysis of financial condition and results of operations this discussion contains forward looking statements and such statements are subject to certain risks and uncertainties which could cause actual results to differ materially from those projected 
factors that could cause or contribute to such differences include  but are not limited to  the factors discussed below and in business and additional business risks  as well as those discussed elsewhere in this annual report on form k 
overview since its inception  the company has been engaged in the discovery and development of novel therapeutics including both small molecule drugs and therapeutic viruses which are based upon the genetics of human disease 
the company has initially chosen to focus its research in the area of cancer 
the company intends to pursue its therapeutic discovery programs independently and in collaboration with pharmaceutical companies  and to collaborate with such companies on the development and commercialization of any products which may result from the company s discovery programs 
the company has entered into collaborative agreements with bayer in the area of ras oncogenes and eli lilly on the function of the brca gene in breast cancer 
the company has also entered into two separate collaborative agreements with warner lambert  one in cell cycle mutations in cancer and a second pertaining to inflammation and autoimmunity 
the company has not been profitable since inception and expects to incur substantial and increasing losses for the foreseeable future  primarily due to the expansion of its research and development programs  including preclinical studies and clinical trials 
the company expects that losses will fluctuate from quarter to quarter and that such fluctuations may be substantial 
as of december   the company s accumulated deficit was approximately million 
the company s business is subject to significant risks  including the risks inherent in its research and development efforts  uncertainties associated with obtaining and enforcing patents  the lengthy and expensive regulatory approval process and competition from other products 
the company does not expect to generate revenues from the sale of proposed products in the foreseeable future 
results of operations years ended december   and revenue revenue from collaborative research and development agreements contract revenue with bayer  eli lilly and warner lambert accounted for approximately of the company s total revenue for this three year period 
contract revenue for the years ended december   and was million  million and million  respectively 
contract revenue recorded from bayer accounted for approximately million or of total contract revenue for  million or of total contract revenue for and million or of total contract revenue for contract revenue recorded from eli lilly accounted for approximately million or of total contract revenue in   or of total contract revenue in and  or of total contract revenue in contract revenue recorded from warner lambert for the cell cycle program accounted for approximately million or of total contract revenue in  million or of total contract revenue in and million or of total contract revenue in in  no funds were received and no revenue was recognized from warner lambert for the inflammation agreement 
the company anticipates that its contract revenue for will exceed the amount of such revenue recognized in research and development expenses research and development expenses were million  million and million during the years ended december   and  respectively 
the expense increase of was primarily due to additional clinical costs associated with phase i and phase ii clinical trials of onyx  the lead product in the company s p program 
the expense increase of was due to increased payroll and personnel expenses as the company hired additional research and development staff and increased expenses in connection with the preclinical and clinical development of onyx pursuant to the cell cycle collaboration with warner lambert  the company is currently obligated to fund its research and development  net of payments from warner lambert  at a level of approximately million annually through may research under the existing agreements with bayer  eli lilly and warner lambert for inflammation  is fully funded by the collaborative partners up to specified levels 
the company expects to continue to expand the scope of its research and development programs significantly in future periods  which will result in substantial increases in research and development expenses  including costs associated with clinical development of onyx in the p therapeutic virus program 
these research and development expenses may not be funded by collaborative partners 
general and administrative expenses general and administrative expenses were million  million and million during the years ended december   and  respectively 
the increases in each period  in and in were primarily due to increased administrative staffing and higher expenses in connection with the company s reporting and other requirements associated with operating as a publicly held company 
net interest income the company had net interest income of million  million and  during the years ended december   and  respectively 
interest income increased each year from to due to a higher average balance of cash  cash equivalents and short term investments resulting from the company s initial public offering of common stock in may the ipo and an equity investment of million from warner lambert in may interest expense has declined as the company has reduced its obligations under debt financing agreements 
however  in december  the company drew down million on its line of credit which will increase the amount of interest expense over the next three years 
liquidity and capital resources since inception  the company s cash expenditures have substantially exceeded its revenues and the company has relied primarily on the proceeds from the sale of equity securities and revenue from collaborative research and development agreements to fund its operations 
at december   the company had cash and investments of million compared to million and million at december  and  respectively 
the decrease of million in was due to cash used in operations of million and capital expenditures of million offset by debt financing of million and a warner lambert equity investment of million 
the increase in cash and investments of million in was due to million of net proceeds from the ipo and million from a warner lambert equity investment offset by cash used in operations of million 
the decrease in cash and investments of million during was primarily due to cash used in operations of million offset by net proceeds from the warner lambert and eli lilly equity investments of an aggregate of million 
the company s cash used in operations was million in  million in  and million in this cash was used primarily to fund increasing levels of research and development and the general and administrative expenses necessary to support increased operations 
capital expenditures amounted to million in as compared to million in  and  in the company expects to make expenditures for capital additions of approximately million in in january  the company raised an additional million of cash  bringing the cash and investment balance to approximately million  by issuing  shares of common stock to two institutional investors 
the company records and amortizes over the related vesting periods deferred compensation representing the difference between the exercise price of options granted and the deemed fair value of its common stock at the time of grant 
options generally vest over four years 
deferred compensation of  and  was recorded in and  respectively 
the amortization of deferred compensation was   and  respectively  for the years ended december   and amortization of deferred compensation over the next two fiscal years  including compensation recognized to date  will aggregate to  as such options vest 
the company believes that its existing capital resources and interest thereon  and anticipated revenues from existing collaborations will be sufficient to fund its current and planned operations through there can be no assurance  however  that changes in the company s research and development plans or other changes affecting the company s operating expenses will not result in the expenditure of such resources before such time  and in any event  the company will need to raise substantial additional capital to fund its operations in future periods 
the company intends to seek such additional funding through collaborative arrangements  public and private equity or debt financings  capital lease transactions or other financing sources that may be available 
however  there can be no assurance that additional financing will be available on acceptable terms or at all 
if additional funds are raised by issuing equity securities  substantial dilution to existing stockholders may result 
if adequate funds are not available  the company may be required to delay  reduce the scope of  or eliminate one or more of its research or development programs or to obtain funds through collaborative arrangements with others that are on unfavorable terms or that may require the company to relinquish rights to certain of its technologies  product candidates or products that the company would otherwise seek to develop itself 
impact of the year computer programs using two rather than four digits to identify the year in a date field may cause computer systems to malfunction in the year any computer programs that have time related software may determine a date using as the year rather than the year this could result in a system failure or miscalculations causing disruptions of operations including  among other things  a temporary inability to engage in specific business activities 
based on a recent assessment  the company has determined that it will be required to upgrade or replace a portion of its software so that its computer systems will function properly with respect to dates in the year and thereafter 
the company believes that  with upgrades of existing software and or conversions to new software  the year issue will not pose significant operational problems for its business activities 
the company anticipates that its costs associated with the upgrade and or conversion of existing computer software relating to the year issue is less than  however  there can be no assurance that these estimates will be achieved  and actual results could differ materially from those anticipated 
specific factors that might cause such material differences include  but are not limited to  the availability and cost of personnel trained in this area  the ability to locate and correct all relevant computer codes and similar uncertainties 
the company has also initiated communications with its significant suppliers to determine the extent to which the company s operations are vulnerable to those third parties failure to solve their own year issues 
there can be no assurance that the systems of other companies on which the company relies will be converted on a timely basis and will not have an adverse effect on the company s operations 
item a 
quantitative and qualitative disclosures about market risk not applicable 

